Crohn's disease
Wellcome Sanger Institute, Open Targets Fund Inflammatory Bowel Disease Biomarker Study
Researchers will analyze multiomic and clinical data from 1,000 patients with IBD recruited from seven participating hospitals in the UK.
Merck Closes $10.8B Prometheus Biosciences Acquisition
Prometheus' lead candidate being developed for ulcerative colitis and Crohn's disease, PRA-023, will be renamed MK-7240.
Merck to Acquire Prometheus Biosciences for $10.8B
Prometheus' lead candidate is PRA023, a monoclonal antibody it's testing to treat ulcerative colitis, Crohn's disease, and other autoimmune conditions.
The CDPath prognostic tool gives Crohn's patients risk scores for serious complications within three years, so they can make more informed treatment decisions.
The Seattle-based company recently published immune repertoire data showing the potential of T-cell receptor profiling in IBD diagnostics.